Avinainder Singh, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Amyloid Neuropathies, Familial | 6 | 2024 | 151 | 1.930 |
Why?
|
Myocardial Infarction | 29 | 2024 | 11460 | 1.690 |
Why?
|
Registries | 24 | 2024 | 8224 | 1.070 |
Why?
|
Amyloidosis | 6 | 2022 | 817 | 0.860 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2021 | 3245 | 0.810 |
Why?
|
Cardiovascular System | 2 | 2020 | 834 | 0.780 |
Why?
|
Heart Injuries | 2 | 2020 | 206 | 0.760 |
Why?
|
Prealbumin | 4 | 2022 | 222 | 0.750 |
Why?
|
Lipoprotein(a) | 5 | 2024 | 480 | 0.530 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2019 | 395 | 0.460 |
Why?
|
Eligibility Determination | 1 | 2017 | 421 | 0.450 |
Why?
|
Cardiovascular Diseases | 9 | 2024 | 15500 | 0.330 |
Why?
|
Coronary Artery Disease | 6 | 2024 | 6403 | 0.320 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2018 | 1073 | 0.320 |
Why?
|
Atherosclerosis | 5 | 2024 | 3408 | 0.310 |
Why?
|
Cardiomyopathies | 5 | 2024 | 1964 | 0.260 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 1640 | 0.250 |
Why?
|
Out-of-Hospital Cardiac Arrest | 2 | 2019 | 339 | 0.240 |
Why?
|
Marijuana Abuse | 2 | 2018 | 411 | 0.230 |
Why?
|
Benzoxazoles | 1 | 2024 | 90 | 0.230 |
Why?
|
Heart Failure | 6 | 2022 | 11669 | 0.210 |
Why?
|
Retrospective Studies | 25 | 2024 | 80636 | 0.200 |
Why?
|
Technetium | 2 | 2022 | 317 | 0.200 |
Why?
|
Middle Aged | 43 | 2024 | 220895 | 0.200 |
Why?
|
Adenine | 3 | 2022 | 987 | 0.190 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2021 | 42 | 0.190 |
Why?
|
Heart Diseases | 3 | 2019 | 2781 | 0.180 |
Why?
|
Risk Factors | 20 | 2024 | 74206 | 0.180 |
Why?
|
Humans | 65 | 2024 | 761504 | 0.180 |
Why?
|
Young Adult | 13 | 2022 | 59243 | 0.180 |
Why?
|
Exercise Test | 2 | 2019 | 2127 | 0.180 |
Why?
|
Male | 45 | 2024 | 360804 | 0.180 |
Why?
|
Female | 46 | 2024 | 392644 | 0.170 |
Why?
|
Coronary Angiography | 5 | 2020 | 4471 | 0.170 |
Why?
|
International Classification of Diseases | 3 | 2019 | 909 | 0.170 |
Why?
|
Myeloma Proteins | 1 | 2019 | 71 | 0.160 |
Why?
|
Risk Assessment | 12 | 2024 | 23995 | 0.160 |
Why?
|
Piperidines | 3 | 2022 | 1656 | 0.160 |
Why?
|
Prognosis | 13 | 2024 | 29625 | 0.150 |
Why?
|
Hypoglycemic Agents | 3 | 2020 | 3085 | 0.150 |
Why?
|
Cholesterol, LDL | 2 | 2019 | 2382 | 0.140 |
Why?
|
Age of Onset | 3 | 2021 | 3305 | 0.140 |
Why?
|
Health Services Misuse | 1 | 2019 | 244 | 0.140 |
Why?
|
Patient Readmission | 3 | 2020 | 3270 | 0.140 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1008 | 0.140 |
Why?
|
United States Food and Drug Administration | 3 | 2020 | 1664 | 0.130 |
Why?
|
Drug Labeling | 1 | 2018 | 248 | 0.130 |
Why?
|
Massachusetts | 5 | 2020 | 8830 | 0.130 |
Why?
|
Patient Care Management | 1 | 2019 | 302 | 0.130 |
Why?
|
Hypolipidemic Agents | 1 | 2020 | 609 | 0.130 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 311 | 0.130 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2017 | 179 | 0.130 |
Why?
|
Diabetes Mellitus | 3 | 2024 | 5840 | 0.120 |
Why?
|
Adult | 21 | 2024 | 221177 | 0.120 |
Why?
|
Aged | 25 | 2024 | 169289 | 0.120 |
Why?
|
Oligopeptides | 1 | 2020 | 1187 | 0.120 |
Why?
|
Boston | 5 | 2019 | 9326 | 0.120 |
Why?
|
Cholesterol | 2 | 2021 | 2904 | 0.120 |
Why?
|
Health Status Indicators | 1 | 2020 | 970 | 0.120 |
Why?
|
Cocaine-Related Disorders | 1 | 2018 | 461 | 0.120 |
Why?
|
Diabetic Angiopathies | 1 | 2019 | 803 | 0.120 |
Why?
|
Prevalence | 6 | 2024 | 15732 | 0.120 |
Why?
|
Troponin | 1 | 2018 | 502 | 0.110 |
Why?
|
Radionuclide Imaging | 1 | 2018 | 1972 | 0.110 |
Why?
|
Tendon Injuries | 1 | 2017 | 328 | 0.110 |
Why?
|
Central Nervous System Diseases | 1 | 2018 | 520 | 0.110 |
Why?
|
Cocaine | 1 | 2018 | 958 | 0.110 |
Why?
|
Immunoglobulin M | 1 | 2018 | 1527 | 0.110 |
Why?
|
Heart | 2 | 2018 | 4404 | 0.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 11742 | 0.100 |
Why?
|
Stroke Volume | 3 | 2021 | 5496 | 0.100 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 3879 | 0.100 |
Why?
|
United States | 14 | 2021 | 72334 | 0.100 |
Why?
|
Aortic Valve Insufficiency | 1 | 2016 | 576 | 0.100 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58976 | 0.100 |
Why?
|
Cohort Studies | 9 | 2022 | 41487 | 0.100 |
Why?
|
Diagnostic Errors | 1 | 2019 | 1265 | 0.100 |
Why?
|
Dyslipidemias | 1 | 2019 | 868 | 0.090 |
Why?
|
Cyclophosphamide | 3 | 2022 | 2218 | 0.090 |
Why?
|
Arrhythmias, Cardiac | 1 | 2021 | 2244 | 0.090 |
Why?
|
Coronary Stenosis | 1 | 2017 | 794 | 0.090 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2192 | 0.090 |
Why?
|
Patient Discharge | 2 | 2020 | 3443 | 0.090 |
Why?
|
Recovery of Function | 1 | 2020 | 2979 | 0.080 |
Why?
|
Hospital Mortality | 5 | 2022 | 5294 | 0.080 |
Why?
|
Vidarabine | 2 | 2021 | 336 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2018 | 1670 | 0.080 |
Why?
|
Cause of Death | 4 | 2021 | 3683 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2009 | 0.080 |
Why?
|
Sex Factors | 2 | 2020 | 10552 | 0.080 |
Why?
|
Intention to Treat Analysis | 2 | 2020 | 413 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2020 | 2056 | 0.080 |
Why?
|
Mortality | 4 | 2021 | 2901 | 0.080 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15842 | 0.080 |
Why?
|
Sarcoidosis | 1 | 2013 | 521 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2019 | 2118 | 0.070 |
Why?
|
Lipids | 1 | 2019 | 3341 | 0.070 |
Why?
|
Time Factors | 5 | 2024 | 39967 | 0.070 |
Why?
|
Pyrimidines | 1 | 2019 | 3028 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2759 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2190 | 0.070 |
Why?
|
Treatment Outcome | 10 | 2022 | 64680 | 0.070 |
Why?
|
Incidence | 5 | 2024 | 21353 | 0.070 |
Why?
|
Comorbidity | 4 | 2021 | 10508 | 0.060 |
Why?
|
Survival Analysis | 4 | 2019 | 10090 | 0.060 |
Why?
|
Electrocardiography | 1 | 2019 | 6377 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2020 | 12148 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5671 | 0.060 |
Why?
|
Kidney Failure, Chronic | 1 | 2018 | 2471 | 0.060 |
Why?
|
Proportional Hazards Models | 4 | 2022 | 12463 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2010 | 0.060 |
Why?
|
Thrombosis | 1 | 2019 | 2942 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3429 | 0.060 |
Why?
|
Echocardiography | 1 | 2016 | 4989 | 0.060 |
Why?
|
Dementia | 1 | 2018 | 2686 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6484 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4652 | 0.050 |
Why?
|
Anticoagulants | 1 | 2019 | 4812 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39106 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 84 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5146 | 0.050 |
Why?
|
Aspirin | 1 | 2014 | 3133 | 0.050 |
Why?
|
Genotype | 1 | 2017 | 12990 | 0.050 |
Why?
|
Age Factors | 4 | 2019 | 18395 | 0.050 |
Why?
|
Survival Rate | 3 | 2021 | 12725 | 0.050 |
Why?
|
Research Design | 1 | 2017 | 6180 | 0.050 |
Why?
|
Immunoglobulin Variable Region | 1 | 2022 | 419 | 0.050 |
Why?
|
Cardiac Electrophysiology | 1 | 2021 | 59 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2017 | 4811 | 0.040 |
Why?
|
Product Labeling | 1 | 2020 | 76 | 0.040 |
Why?
|
Socioeconomic Factors | 2 | 2024 | 7827 | 0.040 |
Why?
|
Phenotype | 1 | 2017 | 16591 | 0.040 |
Why?
|
Knowledge | 1 | 2020 | 177 | 0.040 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2021 | 506 | 0.040 |
Why?
|
Death Certificates | 1 | 2018 | 167 | 0.040 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2017 | 82 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 790 | 0.040 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2017 | 169 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 6485 | 0.040 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 709 | 0.030 |
Why?
|
Rupture, Spontaneous | 1 | 2017 | 362 | 0.030 |
Why?
|
Hospitalization | 3 | 2021 | 10723 | 0.030 |
Why?
|
Rhabdomyolysis | 1 | 2018 | 152 | 0.030 |
Why?
|
Economics, Hospital | 1 | 2018 | 210 | 0.030 |
Why?
|
Paraproteinemias | 1 | 2019 | 248 | 0.030 |
Why?
|
Public Opinion | 1 | 2020 | 484 | 0.030 |
Why?
|
Hospitals | 2 | 2019 | 3882 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2021 | 836 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2122 | 0.030 |
Why?
|
Up-Regulation | 1 | 2024 | 4124 | 0.030 |
Why?
|
Thoracic Injuries | 1 | 2018 | 288 | 0.030 |
Why?
|
Echocardiography, Doppler | 1 | 2019 | 897 | 0.030 |
Why?
|
Angina, Unstable | 1 | 2019 | 888 | 0.030 |
Why?
|
Obesity | 1 | 2017 | 12947 | 0.030 |
Why?
|
Arm | 1 | 2017 | 589 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2017 | 492 | 0.030 |
Why?
|
Primary Prevention | 1 | 2021 | 1186 | 0.030 |
Why?
|
Rubidium Radioisotopes | 1 | 2013 | 77 | 0.030 |
Why?
|
Plasma Cells | 1 | 2017 | 599 | 0.030 |
Why?
|
Chest Pain | 1 | 2020 | 1091 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2021 | 2426 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12059 | 0.030 |
Why?
|
Dexamethasone | 1 | 2020 | 1948 | 0.030 |
Why?
|
Drug Utilization | 1 | 2019 | 1188 | 0.030 |
Why?
|
Medication Adherence | 1 | 2024 | 2176 | 0.030 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 840 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1913 | 0.030 |
Why?
|
Age Distribution | 1 | 2018 | 2880 | 0.030 |
Why?
|
Amyloid | 1 | 2017 | 841 | 0.020 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2019 | 1050 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 22176 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3416 | 0.020 |
Why?
|
Echocardiography, Transesophageal | 1 | 2016 | 1086 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2827 | 0.020 |
Why?
|
Antibodies | 1 | 2017 | 2418 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2498 | 0.020 |
Why?
|
Perfusion | 1 | 2013 | 1373 | 0.020 |
Why?
|
Perioperative Care | 1 | 2016 | 1033 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2018 | 1792 | 0.020 |
Why?
|
Acute Disease | 1 | 2019 | 7237 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1852 | 0.020 |
Why?
|
Hemodynamics | 1 | 2016 | 4159 | 0.020 |
Why?
|
Disease Progression | 1 | 2022 | 13506 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3358 | 0.020 |
Why?
|
Coronary Disease | 1 | 2019 | 5914 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4420 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1880 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2018 | 2567 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 2651 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7390 | 0.010 |
Why?
|
Smoking | 1 | 2020 | 9053 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2018 | 4330 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2014 | 2751 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13255 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9646 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 88319 | 0.010 |
Why?
|
Hypertension | 1 | 2021 | 8540 | 0.010 |
Why?
|
Myocardium | 1 | 2013 | 4726 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15266 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42230 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12953 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14605 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54425 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10773 | 0.010 |
Why?
|
Animals | 1 | 2017 | 168459 | 0.000 |
Why?
|